Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2012 2
2016 1
2018 1
2021 1
2023 4
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.
Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW, Wang J, Poddubskaya E, Pan H, Rha SY, Zhang R, Hirano H, Spigel D, Yamaguchi K, Chao Y, Wyrwicz L, Disel U, Cid RP, Fornaro L, Evesque L, Wang H, Xu Y, Li J, Sheng T, Yang S, Li L, Moehler M, Xu RH; RATIONALE-305 Investigators. Qiu MZ, et al. Among authors: arkenau t. BMJ. 2024 May 28;385:e078876. doi: 10.1136/bmj-2023-078876. BMJ. 2024. PMID: 38806195 Clinical Trial.
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, Palmieri C, Chap LI, Richards P, Gradishar W, Sardesai S, Melear J, O'Shaughnessy J, Ward P, Chalasani P, Arkenau T, Baird RD, Jeselsohn R, Ali S, Clack G, Bahl A, McIntosh S, Krebs MG. Coombes RC, et al. Among authors: arkenau t. Nat Commun. 2023 Jul 24;14(1):4444. doi: 10.1038/s41467-023-40061-y. Nat Commun. 2023. PMID: 37488191 Free PMC article. Clinical Trial.
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.
Burris HA, Berlin J, Arkenau T, Cote GM, Lolkema MP, Ferrer-Playan J, Kalapur A, Bolleddula J, Locatelli G, Goddemeier T, Gounaris I, de Bono J. Burris HA, et al. Among authors: arkenau t. Br J Cancer. 2024 Apr;130(7):1131-1140. doi: 10.1038/s41416-023-02436-2. Epub 2024 Jan 29. Br J Cancer. 2024. PMID: 38287179 Free PMC article. Clinical Trial.
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, Palmieri C, Chap LI, Richards P, Gradishar W, Sardesai S, Melear J, O'Shaughnessy J, Ward P, Chalasani P, Arkenau T, Baird RD, Jeselsohn R, Ali S, Clack G, Bahl A, McIntosh S, Krebs MG. Coombes RC, et al. Among authors: arkenau t. Nat Commun. 2023 Aug 7;14(1):4741. doi: 10.1038/s41467-023-40561-x. Nat Commun. 2023. PMID: 37550302 Free PMC article. No abstract available.
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.
Kristeleit R, Plummer R, Jones R, Carter L, Blagden S, Sarker D, Arkenau T, Evans TRJ, Danson S, Symeonides SN, Veal GJ, Klencke BJ, Kowalski MM, Banerji U. Kristeleit R, et al. Among authors: arkenau t. Br J Cancer. 2023 Jul;129(1):38-45. doi: 10.1038/s41416-023-02279-x. Epub 2023 Apr 29. Br J Cancer. 2023. PMID: 37120671 Free PMC article. Clinical Trial.
Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Flaherty KT, et al. N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4. N Engl J Med. 2012. PMID: 22663011 Free article. Clinical Trial.
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
Jones R, Plummer R, Moreno V, Carter L, Roda D, Garralda E, Kristeleit R, Sarker D, Arkenau T, Roxburgh P, Walter HS, Blagden S, Anthoney A, Klencke BJ, Kowalski MM, Banerji U. Jones R, et al. Among authors: arkenau t. Clin Cancer Res. 2023 Jan 17;29(2):331-340. doi: 10.1158/1078-0432.CCR-22-2074. Clin Cancer Res. 2023. PMID: 36378548 Free PMC article. Clinical Trial.
Phase I Cancer Trials and Palliative Care: Antagonism, Irrelevance, or Synergy?
Cassel JB, Del Fabbro E, Arkenau T, Higginson IJ, Hurst S, Jansen LA, Poklepovic A, Rid A, Rodón J, Strasser F, Miller FG. Cassel JB, et al. Among authors: arkenau t. J Pain Symptom Manage. 2016 Sep;52(3):437-45. doi: 10.1016/j.jpainsymman.2016.02.014. Epub 2016 May 24. J Pain Symptom Manage. 2016. PMID: 27233136 Free article.
A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma.
Chowdhury S, Infante JR, Hawkins R, Voss MH, Perini R, Arkenau T, Voskoboynik M, Aimone P, Naeije I, Reising A, McDermott DF. Chowdhury S, et al. Among authors: arkenau t. Clin Genitourin Cancer. 2021 Oct;19(5):434-446. doi: 10.1016/j.clgc.2021.04.007. Epub 2021 Apr 20. Clin Genitourin Cancer. 2021. PMID: 34006498 Free PMC article. Clinical Trial.
13 results